Sanofi/Regeneron's IL-4 and IL-13 inhibitor Dupixent (dupilumab) was approved to treat CRSwNP in 2019, and was joined on the US market by GSK's IL-5 inhibitor Nucala (mepolizumab) last year.

GSK posted a healthy 13% increase in second-quarter sales this morning and raised its forecasts for the year on the back of gains for its cancer and HIV drugs, beating market expectations.

Calling people "mentally ill" based on their sexual identity and referring to women as "household objects" will now be allowed in the context of political discussions on social media giant Meta's ...

Real estate giant Dar Global said it plans to expand in the U.S. and Greece after the Dubai-based developer recently unveiled projects in partnership with the Trump Organization, Reuters reported ...

January 9, 2025 • The New York Stock Exchange and the Nasdaq will both observe Thursday's national day of mourning in a Wall Street tradition dating back to 1865.

In response to the devastating fires across Los Angeles, Princess Cruises provides aid and flexible cancellation options to impacted passengers.